Literature DB >> 7818242

The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease.

T Saitoh1, Y Xia, X Chen, E Masliah, D Galasko, C Shults, L J Thal, L A Hansen, R Katzman.   

Abstract

Approximately one-fourth of neuropathologically confirmed cases of Alzheimer's disease (AD) also have brainstem and neocortical Lewy bodies, constituting a Lewy body variant of AD. Because Lewy bodies are a pathologic hallmark of Parkinson's disease (PD), this subpopulation of AD subjects may have the same risk factors as PD subjects. Analyses of the cytochrome P450 CYP2D6-debrisoquine 4-hydroxylase mutant B allele, a susceptibility gene for PD, revealed a higher representation of this allele in the Lewy body variant of AD than in pure AD or non-AD without Lewy bodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7818242     DOI: 10.1002/ana.410370120

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  9 in total

Review 1.  Drug-metabolizing cytochrome P450s in the brain.

Authors:  Sharon L Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 3.  Epidemiology of the dementias: recent developments and new approaches.

Authors:  C M van Duijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

4.  Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.

Authors:  Federica Varsaldi; Gianluca Miglio; Maria Gabriella Scordo; Marja-Liisa Dahl; Laura Maria Villa; Aldo Biolcati; Grazia Lombardi
Journal:  Eur J Clin Pharmacol       Date:  2006-07-15       Impact factor: 2.953

5.  Septin 3 gene polymorphism in Alzheimer's disease.

Authors:  Masanori Takehashi; Tyler Alioto; Todd Stedeford; Amanda S Persad; Marek Banasik; Eliezer Masliah; Seigo Tanaka; Kunihiro Ueda
Journal:  Gene Expr       Date:  2004

Review 6.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Dementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer's disease.

Authors:  Robert E Mrak; W Sue T Griffin
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

8.  A comprehensive screening of copy number variability in dementia with Lewy bodies.

Authors:  Celia Kun-Rodrigues; Tatiana Orme; Susana Carmona; Dena G Hernandez; Owen A Ross; John D Eicher; Claire Shepherd; Laura Parkkinen; Lee Darwent; Michael G Heckman; Sonja W Scholz; Juan C Troncoso; Olga Pletnikova; Ted Dawson; Liana Rosenthal; Olaf Ansorge; Jordi Clarimon; Alberto Lleo; Estrella Morenas-Rodriguez; Lorraine Clark; Lawrence S Honig; Karen Marder; Afina Lemstra; Ekaterina Rogaeva; Peter St George-Hyslop; Elisabet Londos; Henrik Zetterberg; Imelda Barber; Anne Braae; Kristelle Brown; Kevin Morgan; Claire Troakes; Safa Al-Sarraj; Tammaryn Lashley; Janice Holton; Yaroslau Compta; Vivianna Van Deerlin; Geidy E Serrano; Thomas G Beach; Suzanne Lesage; Douglas Galasko; Eliezer Masliah; Isabel Santana; Pau Pastor; Monica Diez-Fairen; Miquel Aguilar; Pentti J Tienari; Liisa Myllykangas; Minna Oinas; Tamas Revesz; Andrew Lees; Brad F Boeve; Ronald C Petersen; Tanis J Ferman; Valentina Escott-Price; Neill Graff-Radford; Nigel J Cairns; John C Morris; Stuart Pickering-Brown; David Mann; Glenda M Halliday; John Hardy; John Q Trojanowski; Dennis W Dickson; Andrew Singleton; David J Stone; Rita Guerreiro; Jose Bras
Journal:  Neurobiol Aging       Date:  2018-10-24       Impact factor: 4.673

Review 9.  Dementia with Lewy bodies: disease concept and genetics.

Authors:  Manuel B Graeber; Ulrich Müller
Journal:  Neurogenetics       Date:  2003-07-26       Impact factor: 2.660

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.